Overview
Swiss investment firm's 2025 prelim net profit rose to CHF 578 mln from CHF 76 mln in 2024
Company's shares outperformed Nasdaq Biotech Index with 53.7% total return in USD
Dividend proposal increased to CHF 2.25 per share, reflecting a 5% yield
Outlook
Company proposes regular dividend of CHF 2.25 per share for 2026
BB Biotech to publish detailed 2026 outlook in Annual Report on February 20, 2026
Result Drivers
NET PROFIT INCREASE - Co reported net profit of CHF 578 mln for 2025, up from CHF 76 mln in 2024
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
CHF 578 mln
FY Dividend
CHF 2.25
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for BB Biotech AG is CHF57.72, about 17% above its January 22 closing price of CHF49.35
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 6 three months ago
Press Release: ID:nEQttXmQa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
